SUMMARY: SITUATION OF USING DRUGS FOR GOUT TREATMENT OF INPATIENTS

Abstract


 Objective: To describe the current situation of using drugs to treat gout on inpatients at Can Tho City General Hospital. Subjects and methods: Retrospective, cross-sectional, descriptive, non-intervention study based on inpatient medical records for gout treatment at Can Tho City General Hospital with admission time from June 2019 to December 2019. Results: The majority of patients were prescribed colchicine, accounting for 91.35%, followed by oral and injected meloxicam, with 55.77.0% and 29.81% respectively. Inpatients using a single regimen mainly used paracetamol (accounting for 36.11%) and colchicine (accounting for 22.22%). The most commonly used 2-drug inpatient regimen included: colchicin + oral paracetamol (30.43%), oral meloxicam + oral paracatamol (19.57%). The 3-drug combination regimen on the inpatient group includes: colchicin + injected meloxicam + oral paracetamol (accounting for 61.11%). The four-drug combination regimen was colchicin + injected meloxicam + oral methylprednisolon + infused paracetamol. The majority of inpatients had the regimen changed due to improved clinical symptoms (accounting for 64.13%). Approximately 25.54% of patients need changes due to more severe clinical symptoms. Only 6 medical records showed adverse events during the treatment process, accounting for 5.77%. In which, digestive disorders accounted for the highest percentage with 50.0%. Conclusion: Gout inpatients were mainly indicated for the use of colchicin and meloxicam. The main regimens used in monotherapy were paracetamol and colchicin, the multitherapy regimen mainly used colchicin, meloxicam and paracetamol. Drug side effects were low at 5.77%.